Envestnet Asset Management
GEVA

Envestnet Asset Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Envestnet Asset Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6
Closed – – 2903
2014
Q3 		$0 Hold
6
– – ﹤0.01% 2968
2014
Q2 		$1K Sell
6
-6
-50% -$510 ﹤0.01% 2680
2014
Q1 		$1K Hold
12
– – ﹤0.01% 2515
2013
Q4 		$1K Hold
12
– – ﹤0.01% 2424
2013
Q3 		$1K Hold
12
– – ﹤0.01% 2368
2013
Q2 		$1K Buy
+12
New +$547 ﹤0.01% 2303

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Envestnet Asset Management's GEVA Position: Q4 2014 in Review

Envestnet Asset Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2014, closing a stake of 6 shares.

Envestnet Asset Management first reported a position in GEVA in Q2 2013 and held it in 6 quarters. The position peaked at $1K in Q2 2014. 126 funds tracked by Wall St. Rank hold GEVA as of Q4 2014.

  • Envestnet Asset Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2014 after selling out during the quarter.
  • Envestnet Asset Management sold 6 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2014.
  • Envestnet Asset Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 6 quarters.
  • Envestnet Asset Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1K in Q2 2014.
  • 126 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2014.

Based on Envestnet Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.